SCHEMBL4300952

SCHEMBL4300952

CN(Cc1cc(N(C)C)ccn1)Cc1cc(N(C)C)cc(-c2cc(N(C)C)ccn2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 12/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
TERT O14746 1/20 0.32
APP P05067 1/20 0.32
CHRM5 P08912 1/20 0.32
CHKA P35790 1/20 0.32
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303630 0.91 ALDH1A1 (0.35) SIRT2KDM4EALDH1A1GRIN2DGRIN3B
SCHEMBL4308839 0.83 EIF4E (0.34) SIRT2KDM4EALDH1A1
SCHEMBL4315323 0.83 MAP4K4 (0.31) SIRT2KDM4EALDH1A1
SCHEMBL4313244 0.82 KDM4E (0.41) SIRT2KDM4EALDH1A1GRIN2DGRIN3B
SCHEMBL4311559 0.82 KDM4E (0.38) SIRT2KDM4EALDH1A1GRIN2DGRIN3B
SCHEMBL4316270 0.81 KDM4E (0.32) SIRT2KDM4EGRIN2DGRIN3BCHRM1
SCHEMBL4302948 0.79 HRH4 (0.36) GRIN2DGRIN3BCHRM1ADRA1DADRA1A
SCHEMBL4309241 0.78 MAP4K4 (0.33)
SCHEMBL196641 0.77 ALDH1A1 (0.53) SIRT2KDM4EALDH1A1GRIN2DGRIN3B
SCHEMBL15212887 0.76 KDM4E (0.46) SIRT2KDM4EALDH1A1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090044345-A1 Use of Metal Complex Compounds as Oxidation Catalysts CIBA CORP. 2009-02-19 US disclosed
US-20090044345-A1 Use of Metal Complex Compounds as Oxidation Catalysts CIBA CORP. 2009-02-19 US disclosed
US-20090044345-A1 Use of Metal Complex Compounds as Oxidation Catalysts CIBA CORP. 2009-02-19 US disclosed
WO-2007090461-A1 USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS CIBA HOLDING INC. (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090044345-A1 Use of Metal Complex Compounds as Oxidation Catalysts MT-CO2, MT-CO1, SOD1 SIRT2 577/4885KDM4E 3219/4885ALDH1A1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.